This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): UshStat
Description: UshStat is a gene-based therapy for the treatment of Usher syndrome 1B. The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A), which leads to progressive retinitis pigmentosa combined with a congenital hearing defect. UshStat uses the Company's LentiVector gene delivery technology to deliver a corrected version of the MYO7A gene. A single administration of the product could provide long-term or potentially permanent correction.
Oxford BioMedica and Sanofi
In April 2009, Oxford BioMedica entered a collaboration with sanofi-aventis to develop four LentiVector-based products for the treatment of ocular diseases, including StarGen. Oxford BioMedica is responsible for preclinical development and for conducting initial Phase I/II studies.
Oxford BioMedica will receive an upfront payment of US$26 million (18 million pounds) and committed funding of up to a further US$24 million (16 million pounds) over three years. In addition, sanofi-aventis has an exclusive option for a worldwide licence to develop and commercialise four ocular products. If successful, Oxford BioMedica will receive further undisclosed license fees, milestone payments and royalties on product sales.
In June 2012, Oxford BioMedica and Sanofi announced that Sanofi elected to exercise its options to acquire two exclusive worldwide licences for further development, manufacture and commercialisation of StarGen and Ushstat.
Partners: Oxford BioMedica plc
Additional information available to subscribers only: